Pfizer sues India generic drugmaker over cancer drug
Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?
19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
